{"id":"W2105020329","doi":"10.1158/1535-7163.mct-12-1150","title":"Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Fibroblast growth factor receptor 3; Bladder cancer; Cancer research; Fibroblast growth factor receptor; Cancer; Urothelial Cell; Medicine; Fibroblast growth factor receptor 2; Targeted therapy; Monoclonal antibody; Fibroblast growth factor receptor 4; Fibroblast growth factor; Receptor; Antibody; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004112973,0.0002486463,0.0004663199,0.0003214255,0.0002000953,0.0003650368,0.0002236566,0.0003395459,0.001013902],"category_scores_gemma":[0.0002213307,0.0001117443,0.0002171064,0.0002752211,0.0002313385,0.0002056794,0.0001877149,0.0005665551,0.0003444164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006193172,"about_ca_system_score_gemma":0.0005431957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001383891,"about_ca_topic_score_gemma":0.00356674,"domain_scores_codex":[0.999863,0.00004659982,0.000007809604,0.00001761349,0.00003159471,0.00003330101],"domain_scores_gemma":[0.9999574,0.00001116216,0.000009862214,0.00000387176,0.000007910248,0.00000972135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001486074,0.0006895959,0.00754048,0.0004878662,0.00006956188,0.001029368,0.0001668539,0.005052224,0.8017459,0.005279548,0.004533957,0.1719185],"study_design_scores_gemma":[0.00115381,0.01085544,0.03153212,0.0003076164,0.0003496138,0.008821162,0.000290831,0.01179992,0.7520708,0.005473169,0.1772535,0.00009186134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8727846,0.08997469,0.01586061,0.00851588,0.0002348986,0.0002322884,0.000718327,0.0002636672,0.01141508],"genre_scores_gemma":[0.9657838,0.0245917,0.006045166,0.0006410279,0.00007997211,0.00007795553,0.0003506542,0.00002075719,0.002408876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001383891,"threshold_uncertainty_score":0.004493535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02118418005377775,"score_gpt":0.2929432735027572,"score_spread":0.2717590934489795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}